Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy.
Adult
Aged
Enzyme Inhibitors
/ therapeutic use
Female
Glaucoma, Open-Angle
/ physiopathology
Humans
Intraocular Pressure
/ drug effects
Isoquinolines
/ pharmacology
Kaplan-Meier Estimate
Middle Aged
Ocular Hypertension
/ drug therapy
Retrospective Studies
Sulfonamides
/ pharmacology
Trabeculectomy
/ methods
rho-Associated Kinases
/ antagonists & inhibitors
Glaucoma
Ripasudil
Trabeculotomy
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
02 Dec 2019
02 Dec 2019
Historique:
received:
19
02
2019
accepted:
21
11
2019
entrez:
4
12
2019
pubmed:
4
12
2019
medline:
24
3
2020
Statut:
epublish
Résumé
To examine the use of ripasudil as a trabeculotomy outcome marker in patients with primary open-angle glaucoma (POAG). Between May 2015 and December 2018, 35 eyes underwent trabeculotomy and were postoperatively followed for over 3 months. Ripasudil was defined as effective if drug administration resulted in a greater than 10% reduction in intraocular pressure (IOP). Patients were divided into effective (effective group) or non-effective (non-effective group) ripasudil administration groups. The need for additional glaucoma surgery or an IOP ≥ 21 mmHg indicated surgical failure. In both groups, a Kaplan-Meier survival-analysis was used to evaluate success probabilities related to postoperative IOP levels. Effective IOP reduction occurred in 14 of 35 eyes after ripasudil administration, which was shown by a decrease of more than 10%. Postoperatively, both groups exhibited significant reductions of IOP and antiglaucoma medication use for up to 24 months. At 12 and 24 months after trabeculotomy, probabilities of success in the effective vs. non-effective group were 100% vs. 94.7 and 100% vs. 75.4%, respectively (P = 0.14). Trabeculotomy is effective for achieving an IOP < 21 mmHg in ripasudil effective POAG eyes. Examination of ripasudil's IOP-lowering effects may be useful in predicting surgical outcomes after trabeculotomy.
Sections du résumé
BACKGROUND
BACKGROUND
To examine the use of ripasudil as a trabeculotomy outcome marker in patients with primary open-angle glaucoma (POAG).
METHODS
METHODS
Between May 2015 and December 2018, 35 eyes underwent trabeculotomy and were postoperatively followed for over 3 months. Ripasudil was defined as effective if drug administration resulted in a greater than 10% reduction in intraocular pressure (IOP). Patients were divided into effective (effective group) or non-effective (non-effective group) ripasudil administration groups. The need for additional glaucoma surgery or an IOP ≥ 21 mmHg indicated surgical failure. In both groups, a Kaplan-Meier survival-analysis was used to evaluate success probabilities related to postoperative IOP levels.
RESULTS
RESULTS
Effective IOP reduction occurred in 14 of 35 eyes after ripasudil administration, which was shown by a decrease of more than 10%. Postoperatively, both groups exhibited significant reductions of IOP and antiglaucoma medication use for up to 24 months. At 12 and 24 months after trabeculotomy, probabilities of success in the effective vs. non-effective group were 100% vs. 94.7 and 100% vs. 75.4%, respectively (P = 0.14).
CONCLUSIONS
CONCLUSIONS
Trabeculotomy is effective for achieving an IOP < 21 mmHg in ripasudil effective POAG eyes. Examination of ripasudil's IOP-lowering effects may be useful in predicting surgical outcomes after trabeculotomy.
Identifiants
pubmed: 31791272
doi: 10.1186/s12886-019-1253-4
pii: 10.1186/s12886-019-1253-4
pmc: PMC6889586
doi:
Substances chimiques
Enzyme Inhibitors
0
Isoquinolines
0
K-115
0
Sulfonamides
0
rho-Associated Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
243Subventions
Organisme : Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan
ID : 26462689
Références
Ophthalmology. 2015 Dec;122(12):2385-91.e1
pubmed: 26477844
Am J Ophthalmol. 2011 Jun;151(6):1047-1056.e1
pubmed: 21396622
Int Ophthalmol. 2018 Feb;38(1):93-98
pubmed: 28063100
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3216-22
pubmed: 17591891
Arch Ophthalmol. 1993 Dec;111(12):1653-61
pubmed: 8155036
J Glaucoma. 2017 Feb;26(2):96-100
pubmed: 27661993
Adv Ther. 2016 Sep;33(9):1628-34
pubmed: 27438467
Am J Ophthalmol. 2013 Oct;156(4):731-6
pubmed: 23831221
Trans Am Acad Ophthalmol Otolaryngol. 1972 Mar-Apr;76(2):375-83
pubmed: 4582681
Acta Ophthalmol. 2015 Jun;93(4):e254-60
pubmed: 25487877
Clin Ophthalmol. 2016 Jan 28;10:189-206
pubmed: 26869753
Ophthalmic Surg Lasers. 1997 Oct;28(10):810-7
pubmed: 9336773
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):137-44
pubmed: 11133858
JAMA Ophthalmol. 2015 Jul;133(7):755-61
pubmed: 25880207
Graefes Arch Clin Exp Ophthalmol. 2017 Oct;255(10):2009-2015
pubmed: 28711991
Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1029-37
pubmed: 11274082